GlassScriptPhysician profile
Michele C Mack
NPI 1609806272
$4,661.29
in general payments reported to CMS, 2019-2025
31 companies · $2,068 in 2025
The $2,068 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $653 · 2023: $964 · 2024: $855 · 2025: $2,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,887.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,887.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $405.82 | 2022-2025 | |
| Genentech, INC. | $401.91 | 2022-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $330.82 | 2023-2024 | Austedo Xr |
| Evofem Biosciences, INC. | $277.72 | 2021-2025 | Phexxi, Solosec, Phexx |
| Amgen INC. | $275.02 | 2025 | Repatha |
| Novo Nordisk INC | $230.85 | 2022-2023 | |
| Hologic Sales and Service, LLC | $211.67 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Pfizer INC. | $174.49 | 2024-2025 | |
| Abbvie INC. | $150.77 | 2021-2025 | |
| Biogen, INC. | $146.46 | 2025 | Zurzuvae |
| Fresenius Kabi USA, LLC | $145.80 | 2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $132.35 | 2025 | Cobenfy |
| Phathom Pharmaceuticals, INC. | $125.24 | 2025 | Voquezna |
| Astellas Pharma US INC | $125.00 | 2023 | Veozah |
| Abbott Laboratories | $122.63 | 2023 | Freestyle Libre 3 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $121.83 | 2025 | Vyvgart |
| Exeltis, USA INC. | $119.80 | 2022-2025 | Slynd |
| Kiniksa Pharmaceuticals International, Plc | $118.08 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $115.11 | 2022-2025 | Gardasil 9, Gardasil |
| Alnylam Pharmaceuticals INC. | $113.26 | 2024 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $108.67 | 2021-2025 | |
| Agile Therapeutics, INC. | $108.10 | 2022-2024 | Twirla |
| Axsome Therapeutics, INC. | $101.18 | 2025 | Auvelity |
| Sage Therapeutics, LLC | $93.13 | 2025 | Zurzuvae |
| Philips North America LLC | $90.57 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $82.36 | 2025 | Rexulti |
| Organon LLC | $70.08 | 2021-2025 | Nexplanon |
| Exact Sciences Corporation | $56.91 | 2023-2024 | Cologuard Collection Kit |
| Therapeuticsmd, INC. | $41.02 | 2021-2022 | |
| Millicent US INC | $40.05 | 2025 | Femlyv, Intrarosa |
| Supernus Pharmaceuticals, INC. | $24.59 | 2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Mack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.